The first therapeutic effect data of VV116, a small-molecule oral drug for COVID-19 of Junshi Biosciences and Vigonvita, was released this week, captivating the industry.
News about the progress of Chinese small-molecule oral antiviral drug for COVID-19 has been disclosed in recent days and the related R&D ushers in a critical point.